Client NewsOKYO Pharma Limited: Upcoming Presentations at Ophthalmic Conference
OKYO Pharma Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation
BAM8-22 peptide analog OK-201 alleviates neuropathic corneal pain in mice
London, April 27, 2022 – OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announced that two presentations will be given on OKYO drug candidates OK-101 and OK-201 at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held on May 1-4, 2022 in Denver, CO and virtually on May 11-12, 2022.
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.